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Introduction
Plasma cell (PC) leukemia (PCL) is a rare PC disorder that can be considered the leukemic variant of multiple myeloma 
(MM). Two forms of PCL exist: the primary form occurs de novo in patients without a previous history of MM; the sec-
ondary form arises as a rare complication of late-stage disease in patients with MM. Criteria for the diagnosis of PCL have 
been defined by Kyle et al as an absolute PC count > 2000/μL, with PCs comprising > 20% of peripheral blood cells.1-2 
Primary PCL can be considered a distinct clinicopathologic entity, because clinical features, response to chemotherapy, 
and prognosis significantly differ from those of MM.
The clinicopathologic features resemble those of acute leukemia. Bones are less involved, but there is a higher incidence 
of organomegaly and tissue infiltration as well as diffuse marrow involvement and more pronounced cytopenias. Patients 
usually present with anemia and thrombocytopenia, and they have > 50% incidence of hepatosplenomegaly and lymph-
adenopathy (extramedullary involvement) as well as hypercalcemia and impaired renal function.
Commonly, patients with PCL are younger than those with MM. In contrast to MM, PCL has a more aggressive clinical 
course, the disease usually being progressive with a median survival of 6-8 months. In this report, we describe a case of light-chain 
restricted PCL , showing a prolonged survival of 2 years and 6 months and associated with adult Fanconi syndrome. 
 
Clinical Summary
In November 2002, a 60-year-old woman was admitted to the Department of Oncohematology of our University Hospital 
complaining of asthenia and back pain. On presentation, she had anemia (hemoglobin level, 11 g/dL), thrombocytopenia 
(platelet count, 102,000/μL), and renal insufficiency (creatinine level, 2.75 mg/dL; creatinine clearance, 19 mL per minute; 
urea, 71 mg/dL). The white blood cell count was 14,400/μL with 23.6% of plasmacytoid lymphocytes on differential count 
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Primary Plasma Cell Leukemia Associated 
with Adult Fanconi Syndrome
Primary plasma cell leukemia (PCL) is a rare variant of multiple myeloma that occurs de novo in patients without 
a history of plasma cell disorder. We describe a case of  PCL that showed a prolonged survival of 2 years and 
6 months associated with a generalized dysfunction of the proximal renal tubule. On presentation, the patient 
had anemia (hemoglobin level, 11 g/dL), thrombocytopenia (platelet count, 102,000/μL), and renal insufficiency 
(creatinine level, 2.75 mg/dL; creatinine clearance, 19 mL per minute; urea, 71 mg/dL). In addition to the com-
mon clinical picture, our case showed proteinuria (30 mg/dL), glycosuria (150 mg/dL) with normal glycemia, 
low uric acid concentration (2.9 mg/dL), and ion loss from the proximal renal tubule (P, 2.1 mg/dL). These 
findings were compatible with the clinical picture of adult-acquired Fanconi syndrome, which can be observed 
in PCL/multiple myeloma but is almost exclusively associated with -chain restriction.
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Case Report
Abstract
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(3400/μL). On bone marrow smear, marked plasmacytosis was evi-
denced, with PCs accounting for 57% of total cellularity (Figure 1). 
Immunoelectrophoresis revealed a monoclonal  light-chain 
component at a concentration of 9.3 g/L. Immunoglobulin G 
(IgG) concentration was 5 g/L. These findings were consistent with 
the diagnosis of light-chain restricted PCL . 
The serum lactate dehydrogenase value was 468 U/L, and 2-
microglobulin was increased at 47 mg/dL. The patient had protein-
uria (30 mg/dL), glycosuria (150 mg/dL), fasting glucose concentra-
tion (80 mg/dL), hypokalemia (K, 2.9 mEq/L), hypophosphatemia 
(P, 2.1 mg/dL), and low uric acid concentration (2.9 mg/dL).
Neither evidence of bone lesions nor extramedullary involvement 
(hepatomegaly, splenomegaly, or lymphadenopathy) was found. 
In December 2002, treatment with multiagent chemotherapy, a 
combination of vincristine/doxorubicin/dexamethasone (VAD), 
was started. After 3 cycles, the patient exhibited a partial response 
( light-chain component, 1853 g/L; IgG, 2693 g/L), defined as 
a decrease of > 50% in serum or 75% in urine of the monoclonal 
protein associated with the disappearance of circulating PCs. In 
March 2003, she received 1 more cycle of VAD. 
One month later, as a result of disease progression (creatinine 
level, 2.3 mg/dL; 2-microglobulin, 26 mg/dL), therapy with 
VMCP (vincristine/melphalan/cyclophosphamide/prednisolone) 
was started. After 2 cycles, the response was unsatisfactory (IgG, 
3592 g/L;  light chain, 3199 g/L; creatinine level, 2.75 mg/dL; 
2-microglobulin, 17.5 mg/dL), and this regimen was switched 
to vincristine/cyclophosphamide/dexamethasone. After 2 cycles of 
this new regimen, the patient presented severe neutropenia, and 
although the third cycle was deferred (after 29 days), she turned 
leukopenic (leukocyte count, 2500/mL). Therefore, the third and 
fourth cycles were administered at lower dosages.
In October 2003, the patient underwent a bone marrow 
biopsy, which showed slightly hypercellular bone marrow, with 
interstitial, intrasinusoidal, and perisinusoidal infiltration by neo-
plastic PCs (Figure 2) displaying the following phenotypic profile: 
CD44+, -positive, CD138+, epithelial membrane antigen–posi-
tive, CD162+, -negative, CD56–, CD20–, and leukocyte com-
mon antigen–negative. On re-evaluation, disease progression was 
recorded, and therefore thalidomide was started. 
In January 2004, another re-evaluation of the disease was performed, 
and 5 cycles of vincristine/dexamethasone were administered. 
In May 2004, the patient was readmitted to our hospital presenting 
severe renal insufficiency (creatinine level, 3.6 mg/dL; creatinine clear-
ance, 12 mL per minute). Thalidomide was administered as a salvage 
procedure, but because of severe neurotoxicity, the treatment was sub-
sequently stopped. The patient developed progressive, unresponsive dis-
ease and died in May 2005, 2 years and 6 months after presentation.
Bone Marrow Smear
Showing Marked PlasmacytosisFigure 1
Original magnification ×400.
On Immunohistochemistry, Neoplastic
Plasma Cells Show Cytoplasmatic
Expression of  Light Chain
Figure 3
 Anti- light-chain monoclonal antibody (original magnification ×250).
Bone Marrow Biopsy Showing
Interstitial, Intrasinusoidal,
and Perisinusoidal Infiltration
by Neoplastic Plasma Cells 
Figure 2
Original magnification ×250.
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Discussion 
Renal failure has been reported to be a rather frequent adverse 
factor contributing to poor overall survival of patients with primary 
PCL. The occurrence of renal failure in the major reported series of 
primary PCL is summarized in Table 1.2-5
Plasma cell dyscrasia secreting free light chain, exclusively of  
isotype, can be complicated by Fanconi syndrome. Fanconi syn-
drome is a generalized dysfunction of the proximal renal tubule 
characterized by glycosuria with normal glycemia, aminoaciduria, 
phosphaturia, uricosuria, and bicarbonaturia. 
In addition to the common clinical picture, our case showed 
proteinuria (30 mg/dL), glycosuria (150 mg/dL) with normal 
glycemia, low uric acid concentration (2.9 mg/dL), and ion 
loss from the proximal renal tubule (P, 2.1 mg/dL). These find-
ings were compatible with the clinical picture of adult acquired 
Fanconi syndrome. 
 In this disease, the dysfunction of the proximal renal tubule is 
more likely related to  light chains than to  light chains. Fanconi 
syndrome is associated with specific properties of the V domain of 
the  light chain. It has been demonstrated that  variable domains 
are more resistant to protease degradation and have a self-reactivity 
to form crystals. A possible mechanism that explains the dysfunc-
tion of the proximal renal tubule is that light chains in these 
patients cannot undergo complete proteolysis, thus accumulating 
in lysosomal compartments and forming crystal structures in the 
tubular epithelial cells.6
The case we reported showed  light-chain restriction. The asso-
ciation of Fanconi syndrome with  light-chain proteinuria is rare 
and could reflect the different physicochemical properties of the 
light-chain subtypes, specifically their solubility and polymeriza-
tion potential. 
On immunohistochemistry, malignant PCs expressed CD38, cyto-
plasmatic  light chains, CD44 (hyaluronic acid cell adhesion mol-
ecule), CD138 (syndecan-1), CD162 (P-selectin glycoprotein ligand–
1), and epithelial membrane antigen, and were negative for leukocyte 
common antigen, CD20, CD56, and  light chains (Figure 3).
CD38 and CD138 are immunophenotypical markers of PCL. 
CD44 is a homing receptor that plays an important role in leukocyte 
rolling and lymphocyte migration, and it is generally expressed in 
circulating lymphomas migrating in the bone marrow. In PCL, malig-
nant PCs do not express CD56 antigen, which is commonly found in 
myeloma cells.7 CD56 is an adhesion molecule that plays a key role 
in anchoring PCs to the bone marrow stroma. The lack of CD56 is a 
hallmark of PCL, and it is strictly related to the trend of malignant PCs 
to circulate in the peripheral blood and to a lower osteolytic potential.
In addition to this molecule-adhesion profile, we also reported 
the expression of CD162, the major ligand of P-selectin, which has 
recently been described as being a marker of PC differentiation. 
Conclusion 
Response to treatment of PCL is poor. Patients treated with 
standard melphalan and prednisone have a median survival of 2 
months. Those treated with VAD or other aggressive regimens show 
an improved median survival of 20 months.8 In younger patients, 
high-dose chemotherapy with autologous bone marrow or periph-
eral stem cell transplantation should be considered.
References
 1. Kyle RA, Maldonado JE, Bayrd ED. Plasma cell leukaemia: report of 17 cases. Arch 
Intern Med 1974; 113:813-818.
 2.  Costello R, Sainty D, Bouabdallah R, et al. Plasma cell leukaemia: a report of 18 
cases. Leuk Res 2001; 23:103-107. 
3.  García-Sanz R, Orfao A, Gonzalez M, et al. Primary plasma cell leukemia: clinical, 
immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 1999; 
93:1032-1037.
 4. Vela-Ojeda J, Garcia-Ruiz Esparza MA, Rosas-Cabral A, et al. Intermediate doses 
of melphalan and dexamethasone are better than vincristine, adriamycin, and 
dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma 
cell leukemia. Ann Hematol 2002; 81:362-367. 
 5. Jiménez-Zepeda VH, Dominguez-Martinez VJ. Vincristine, doxorubicin, and dex-
amethasone or thalidomide plus dexamethasone for newly diagnosed patients with 
multiple myeloma? Eur J Haematol 2006 [Epub ahead of print].
 6.  Ma CX, Lacy MQ, Rompala JF, et al. Acquired Fanconi syndrome is an indolent 
disorder in the absence of overt multiple myeloma. Blood 2004; 104:40-42.
 7.  Saccaro S, Fonseca R, Veillon DM, et al. Primary plasma cell leukemia: report of 
17 new cases treated with autologous or stem-cell transplantation and review of 
the literature. Am J Hematol 2005; 78:288-294.
 8.  Wohrer S, Ackermann J, Baldia C, et al. Effective treatment of primary plasma cell leu-
kemia with thalidomide and dexamethasone--a case report. Hematol J 2004; 5:361-363.























































Occurrence of Renal Failure in the Major Series of Primary
Plasma Cell Leukemia Reported in the Literature2-5Table 1
Abbreviations: C2H2OP = vincristine/doxorubicin/cyclophosphamide/prednisone; F =  treatment failure; M-80 = melphalan 80 mg/m2 plus dexamethasone 40 mg/m2;
MP = melphalan/prednisone; VBAP = vincristine/bleomycin/doxorubicin/prednisone; VMCPA = vincristine/melphalan/cyclophosphamide/prednisone/doxorubicin
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